Compare Ginkgo Bioworks Holdings Inc (DNA) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Ryanair Holdings plc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.78 (market cap $763.64M), while Ryanair Holdings plc trades at $53.8 (market cap $27.11B). The key difference: Ryanair Holdings plc is far larger — about 35.5× Ginkgo Bioworks Holdings Inc's market cap, and Ryanair Holdings plc pays a 1.66% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Ryanair Holdings plc for 72 Days on average.
| DNA | RYAAY | |
|---|---|---|
Market Cap | $763.64M | $27.11B |
Volume | 3,204,177 | 2,427,380 |
Sector | Health | Industrials |
52-Week High | $15.83 | $73.82 |
52-Week Low | $5.48 | $51.95 |
Typical Hold Time | 7 Days | 72 Days |
Enterprise Value | $865.59M | $24.18B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.
The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.
RYAAY trades at $56.00, up 0.24% on the day, with a bearish technical signal despite strong fundamentals. The company reported $13.95B revenue and $1.61B net income for 2025, with valuation ratios appearing attractive (P/E 13.43, EV/EBITDA 6.05). Recent news highlights CEO commentary on Boeing MAX 10 delays and fuel cost concerns, while analyst consensus remains positive with 65% buy ratings.
RYAAY presents a value opportunity with solid profitability metrics (ROE 22.41%, net margin 12.13%) but faces near-term headwinds from oil price volatility and operational challenges. The stock's current bearish technical positioning contrasts with fundamental strength, creating potential for recovery if fuel costs stabilize and traffic targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
